NCT00333034

Study Evaluating the Safety and Efficacy of Etanercept 50 mg Once Weekly in Subjects With Psoriasis

A Multicenter, Parallel, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Etanercept 50 mg Once Weekly in Subjects With Moderate to Severe Plaque Psoriasis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The primary objective is to assess the efficacy and safety of etanercept 50 mg administered once weekly in subjects with psoriasis over 12 weeks.

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	Etanercept

Timeline

• Start date: 2006-06-01
• Completion: 2007-05-01
• First posted: 2006-06-02
• Last updated: 2007-12-06

Locations

23 sites across 10 countries: Austria, Belgium, France, Germany, Hungary, Italy, Netherlands, Poland, Romania, Spain